Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCPH8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,598
Award facts
- Contract value 100% obligated
- $20,598.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,598.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. This firm fixed-price delivery order, issued on January 20, 2026, with an ultimate completion date of February 10, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, holding a master contract (SPE2DR) with a $499.999 billion ceiling and completion date of December 31, 2036. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with recent delivery orders demonstrating consistent performance across diverse therapeutic categories. This particular delivery order for Stelara, an immunosuppressant biologic agent, reflects the company's capability to fulfill specialized pharmaceutical requirements supporting DOD military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCPH8?
SPE2DR26FCPH8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FCPH8 worth?
The government has obligated $20,598 on SPE2DR26FCPH8.
Is contract SPE2DR26FCPH8 an order under another contract?
Yes. SPE2DR26FCPH8 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPH8 competed?
The extent of competition for SPE2DR26FCPH8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award